Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan
Szu-Min Hsieh, Ming-Che Liu, Yen-Hsu Chen, Wen-Sen Lee, Shinn-Jang Hwang, Shu-Hsing Cheng, Wen-Chien Ko, Kao-Pin Hwang, Ning-Chi Wang, Yu-Lin Lee, Yi-Ling Lin, Shin-Ru Shih, Chung-Guei Huang, Chun-Che Liao, Jian-Jong Liang, Chih-Shin Chang, Charles Chen, Chia En Lien, I-Chen Tai, Tzou-Yien Lin
Topics & Concepts
MedicineImmunogenicityInterimChristian ministryVirologyCpG siteImmunologyVaccinationDNA vaccinationInterim analysisPhase (matter)DiseaseVaccine trialHepatitis A vaccineCpG OligodeoxynucleotideClinical trialAntibodyMEDLINEImmunizationSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesCOVID-19 Impact on Reproduction